最高11亿美元!恒瑞医药再获大单,标的药品将与阿斯利康同类药“掰手腕”

红星新闻
Sep 25

红星资本局9月25日消息,今日,恒瑞医药(600276.SH)公告称,将具有自主知识产权的1类创新药瑞康曲妥珠单抗(SHR-A1811)项目有偿转让给Glenmark Specialty S.A.(下称Glenmark),Glenmark将拥有除中美欧等地区的市场外,SHR-A1811全球范围内的开发及商业化独家权利。Glenmark首期支付恒瑞医药1800万美元,后续恒瑞有资格获得与注册和销售...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10